FCGR3A and cancer: Notably, in addition to the statistics that FcγRIIIa polymorphism affects cancer prognosis, patients with V/V158 genotype also display more clinical benefits than those with F/F158 and F/V158 genotype in the treatment of therapeutic antibodies, including rituximab (Rituxan®), trastuzumab (Herceptin®), cetuximab (Erbitux®), and avelumab (Bavencio®) [35,121,122,123].